Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor ...

Arcus Biosciences and Gilead Sciences have reported promising Phase III results from their ARC-10 study of domvanalimab and ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Arcus Biosciences (NYSE:RCUS – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered with China’s BeiGene.

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...

Arcus Biosciences (RCUS) announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an ...

In a report released yesterday, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – ...

Arcus Biosciences Inc (RCUS) reports robust financial health and strategic advancements in late-stage trials, despite facing ...

Clinical research conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) continues to ...

At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from , Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of ...